PolyTherics and Antitope have completed a merger of their equally sized biopharma services businesses in the U.K., seeking to provide technology and support to the pack of drugmakers in the hunt for biologics such as antibody-drug conjugates.
A monoclonal antibody developed by researchers at the National Institute of Allergy and Infectious Diseases could lay the groundwork for effective therapies against norovirus, which has in recent years infected school campuses, cruise ships, hospitals and nursing homes.
Harbour Antibodies has added to a list of pharma partners for its transgenic mouse technology for producing human antibodies. Pfizer has licensed the company's mice for research of monoclonal antibody drugs, without restrictions on the therapeutic areas the pharma giant can pursue. Financial terms weren't disclosed.
Sorrento Therapeutics and researchers at Israel's Ben-Gurion University of the Negev are partnering to develop anti-hepatitis C antibodies.
Celgene has decisively stepped in to partner on an early-stage myeloma and leukemia drug in MorphoSys's pipeline, paying $92 million upfront, a $60 million premium for a stake in the company and offering to cover a substantial portion of the R&D budget for the antibody targeting the CD38 molecule.
A Belgian biotech staking a claim to fame and fortune on a new approach to protein therapeutics has rounded up $15.5 million in a Series C.
Seattle Genetics, which has a who's who in oncology drug development signed on as ADC collaborators, gets $20 million of that upfront with the rest in milestones.
Boehringer Ingelheim has stepped in to pick up an option on a preclinical cardiovascular program under development at Stockholm-based Athera Biotechnologies, which is part of Karolinska Development's biotech portfolio.
With rates of oral cancer linked to HPV infection on the rise, a group of investigators has pinned down a new biomarker that can be used to identify high-risk patients.
Index Ventures recently completed an $11 million Series A investment in XO1, an asset-centric company established with the sole objective of developing the monoclonal antibody ichorcumab under license from Cambridge University.